EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis

James Signorovitch, Jialu Zhang, David Brown, Preston Dunnmon, Liang Xiu, Nicolae Done, Kristen Hsu, Yolanda Barbachano, Isabelle Lousada

Therapeutic Innovation & Regulatory Science · 2024

DOI: 10.1007/s43441-024-00641-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von James Signorovitch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Analysis Group, Boston, USA. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Clinical Trials as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunoglobin light chain (AL) amyloidosis is a rare disease in which a plasma cell dyscrasia leads to deposition of insoluble amyloid fibrils in multiple organs. To facilitate development of new therapies for this heterogenous disease, a public–private partnership was formed between the nonprofit Amyloidosis Research Consortium and the US Food and Drug Administration Center for Drug Evaluation and Research. In 2020, the Amyloidosis Forum launched an initiative to identify clinical trial endpoints and analytic strategies across affected organ systems and life impacts via specialized working groups. This review summarizes the proceedings of the Statistical Group and proposes a pathway for development and validation of multi-domain endpoints (MDEs) for potential use in AL amyloidosis clinical trials. Specifically, drawing on candidate domain-specific endpoints recommended by each organ-specific working group, different approaches to constructing MDEs were considered. Future studies were identified to assess the validity, meaningfulness and performance of MDEs through use of natural history and clinical trial data. Ultimately, for drug development, the context of use in a regulatory evaluation, the specific patient population, and the investigational therapeutic mechanism should drive selection of appropriate endpoints. MDEs for AL amyloidosis, once developed and validated, will provide important options for advancing patient-focused drug development in this multi-system disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisClinical Trials as TopicHumansDrug DevelopmentEndpoint DeterminationUnited States

Stichwörter der Autor:innen

AL amyloidosisClinical trialMulti-domain endpointsPublic–private partnershipRare diseasesStatistical validation

Autor:innen und Institutionen

  • Analysis Group, Boston, USA.
  • US Food and Drug Administration, Silver Spring, USA.
  • UK Medicines & Healthcare Products Regulatory Agency, London, UK.
  • Janssen Research & Development, Raritan, USA.
  • Amyloidosis Research Consortium, 320 Nevada Street, Suite 210, Newton, MA, 02460, USA.
  • Amyloidosis Research Consortium, 320 Nevada Street, Suite 210, Newton, MA, 02460, USA. ILousada@arci.org.

Förderung

  • NIA NIH HHS
  • National Institute on Aging
  • AbbVie
  • Alexion Pharmaceuticals
  • Caelum
  • GlaxoSmithKline
  • Amyloidosis Research Consortium

Zitieren

APA

Signorovitch, J., Zhang, J., Brown, D., Dunnmon, P., Xiu, L., Done, N., Hsu, K., Barbachano, Y., & Lousada, I. (2024). Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00641-6

Vancouver

Signorovitch J, Zhang J, Brown D, Dunnmon P, Xiu L, Done N, et al. Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00641-6

BibTeX
@article{Signorovitch2024,
  author = {Signorovitch, James and Zhang, Jialu and Brown, David and Dunnmon, Preston and Xiu, Liang and Done, Nicolae and Hsu, Kristen and Barbachano, Yolanda and Lousada, Isabelle},
  title = {Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2024},
  doi = {10.1007/s43441-024-00641-6}
}
Kostenlos starten →